Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2006

View Archived Issues

Preclinical data on the safety of the antithrombotic drug W215A/E217A reported

HuLuc-63 to enter clinical program for multiple myeloma

Safety and pharmacodynamics of SB-559448 reported in healthy subjects

Pregabalin beneficial in patients with spinal cord injury

Snapshots: Phase I clinical studies in hematological malignancies

MedImmune and BioWa to develop inflammatory disease therapies targeting IL-5

Gynecologic Oncology Group to support phase II study of Lovaxin C

CESAR to support enrollment in phase II Davanat study

Novel temperature- and pH-sensitive vaginal gel may be useful to prevent HIV infection

Recent patents report new treatments for metabolic disorders

L- and P- selectin antagonists patented by GlycoMimetics

Recent patents impart novel therapeutic agents for musculoskeletal and connective tissue disorders

Pevion begins clinical testing of virosome-based HCV vaccine

Org-50081 begins phase III for insomnia

EPC-2407 begins phase I study for cancer

Atacicept studied in phase II for rheumatoid arthritis

Hepatitis C protease inhibitor ITMN-191 studied in phase Ia European trial

Altana shareholders approve acquisition by Nycomed

Orexo files to complete phase III program for Sublinox

RheoGene and Intrexon to merge

Exelixis files IND for XL-518

GSK begins phase II studies with collaborative CRF1 receptor antagonist

SGN-40 begins phase II trial for diffuse large B-cell lymphoma

Aztreonam lysine for inhalation meets endpoint in cystic fibrosis study

Ardana announces preliminary results in a phase II study in benign prostatic hyperplasia

Pediatric indication approved for Colazal

FDA approval for Invanz

CV Therapeutics files ranolazine for chronic angina in E.U.

Japanese approval sought for Risperdal Consta

Invega approved for treatment of schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...